Company Overview
BioXcel Therapeutics, Inc. operates as a biopharmaceutical entity that leverages artificial intelligence methodologies to advance drug development within the neuroscience and immuno-oncology therapeutic areas in the United States. The company executes its operations alongside its subsidiary, OnkosXcel Therapeutics LLC, with a specific focus on developing medicines for these specialized medical fields. This enterprise is classified within the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, positioning it among firms that produce specialized pharmaceutical products rather than mass-market generics. The organization maintains a workforce of 37 employees and holds a market capitalization of $30.68M, while reporting trailing twelve-month revenue of $752,000. These financial metrics indicate that the company operates on a very small scale relative to the broader biopharmaceutical industry, reflecting the high capital intensity and long development cycles typical of biotechnology firms that are still in early-stage development phases.
Financial Health
The company reported trailing twelve-month revenue of $752,000, yet posted a net income of $-68,211,000 and an EBITDA of $-50,143,000, revealing a profound disconnect between top-line sales and bottom-line profitability. This significant gap between revenue and net income highlights a cost structure dominated by heavy research and development expenditures or other operational costs that far exceed current sales generation. Free cash flow stands at $-43,281,248, indicating that the company is burning cash to fund its operations and scientific endeavors rather than generating surplus liquidity for dividends or acquisitions. The financial statements show a gross margin of -28.2%, an operating margin of -14320.4%, and a profit margin of 0.0%, all of which reflect the pre-revenue or early-revenue stage losses common in biopharma before product launch. On the balance sheet, the company holds $36.18M in cash against $109.29M in debt, suggesting a leveraged position where liabilities significantly outweigh liquid assets. The debt-to-equity ratio is listed as N/A, which typically occurs in capitalization structures where equity values are nominal or negative due to accumulated losses. Short-term liquidity is constrained with a current ratio of 1.18, indicating that current assets barely cover current liabilities, a precarious position for a firm with negative cash flow. Return on Equity is N/A due to the equity structure, while Return on Assets is -67.3%, demonstrating that the asset base is generating negative returns rather than value for shareholders.
Valuation Assessment
Valuation multiples for the company are highly distorted by its lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -0.62. The negative forward P/E implies that the market is pricing in continued earnings losses rather than established profitability, making traditional earnings-based valuation methods inapplicable. The price-to-book ratio is -0.28, indicating that the market values the company at a fraction of its book value, a metric often seen in distressed or highly speculative biotech firms. Alternative valuation metrics such as the price-to-sales ratio of 40.80 and EV/EBITDA of -2.01 suggest that investors are willing to pay a high multiple relative to sales, yet the negative EV/EBITDA confirms that the company is not generating enough earnings to cover enterprise value. The stock has experienced significant volatility, trading between a 52-week high of $8.08 and a 52-week low of $1.17. Without a specific current price provided in the facts, the valuation context relies on the extreme range between the high and low, illustrating the speculative nature of the investment vehicle. The beta value of 0.23 indicates that the stock exhibits low volatility relative to the broader market, moving less than half the magnitude of the market index on average.
Growth & Income
Revenue growth year-over-year is -54.2%, while earnings growth is N/A due to the absence of positive earnings history. The negative revenue growth suggests a contraction in sales or a shift in the recognition of revenue streams, likely driven by the early-stage nature of the company's pipeline. Earnings are not growing faster than revenue because the company is not profitable, rendering the comparison moot in traditional growth terms. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available resources are theoretically reinvested into research, development, and operational costs rather than distributed to shareholders. This income profile indicates that the company relies entirely on capital markets for funding and does not provide current income to investors. The overall growth and income profile is characterized by negative revenue expansion and zero dividend income, typical of early-stage biopharmaceutical companies focused on long-term asset development rather than short-term financial returns.